How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

187 results for

Vulvar Dermatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

-randomization laboratory testing should fail to identify atrophic vaginitis, dermatitis such as vulvar dystrophy, or pathogens such as fungus, or herpes. The candidate should not report use tricyclic-class or topical lidocaine within 30 days of the study. Candidates will need to be capable of keeping adequate records and demonstrate reliability in use of medication. If the candidate is premenopausal, adequate contraception will be necessary including oral contraceptives, barrier method, progestational (...) Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Vulvar Vestibulitis Clinical Trial

2006 Clinical Trials

182. Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clobetasol Versus Pimecrolimus (...) for Vulvar Lichen Sclerosus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00393263 Recruitment Status : Completed First Posted : October 27, 2006 Last Update Posted : May 12, 2014 Sponsor: Center for Vulvovaginal Disorders Collaborator: Novartis Information provided by (Responsible Party): Andrew T

2006 Clinical Trials

183. [Clobetasol vs. testosterone in the treatment of lichen sclerosus of the vulvar region]. (PubMed)

[Clobetasol vs. testosterone in the treatment of lichen sclerosus of the vulvar region]. The paper describes a study carried out in 40 patients affected by lichen sclerosus (LS) of the vulva. The mean age of patients was 60.9 years (range 27-83) and 31 were in menopause. Patients were divided randomly into two groups of 20. The symptoms (itching, burning, pain, dyspareunia), clinical aspects (atrophy, hyperkeratosis, sclerosis) and histological alterations (atrophy of the epithelium, edema (...) of clinical aspects and histological alterations, and did not cause any noteworthy collateral effects, especially contact dermatitis. In the context of the objective parameters examined in this study, sclerosis and hyperkeratosis were easily modified by corticosteroid treatment in comparison to atrophy, especially in those patients with a longer duration of disease.(ABSTRACT TRUNCATED AT 250 WORDS)

1992 Minerva ginecologica Controlled trial quality: uncertain

184. The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. (PubMed)

feasible, we are investigating new and modified cutaneous test methods to increase the degree of conservatism of the safety assessment. To this end, we have 1) developed a method to assess chemical and frictional effects by means of repeated application to the popliteal fossa (the behind-the-knee test); 2) modified the quantitative risk assessment for the induction of allergic contact dermatitis; and 3) proposed a modified human repeat insult patch test for assessing materials intended for vulvar (...) The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. Vulvar tissue is more permeable than exposed skin due to differences in structure, occlusion, hydration and susceptibility to friction. The safety assessment of products that contact the vulva should account for this potentially heightened permeability. Standard clinical patch tests may not sufficiently mimic vulvar exposures. Because testing on the vulva is not routinely

2004 Contact Dermatitis

185. Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva. (PubMed)

Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva. Irritant and allergic contact dermatitis are commonly seen in patients complaining about itching, burning and irritation in the vulvar area. Irritation often precedes allergic sensitization. Clinically, irritant and allergic contact dermatitis can be difficult to distinguish. Diagnosis is made by history, clinical investigation and patch testing. Recommended patch test series are the standard series, a medicament series (...) , the patient's own topical medicaments, popular remedies and other suspected products. A skin biopsy may be useful to establish the diagnosis of contact dermatitis, but it is usually not helpful for the differential diagnosis between irritant and allergic dermatitis.

2005 Dermatology

186. Multiple parameter assessment of vulvar irritant contact dermatitis. (PubMed)

Multiple parameter assessment of vulvar irritant contact dermatitis. Transepidermal water loss (TEWL), capacitance, pH, blood flow and color reflectance were evaluated for quantifying the irritant response of vulvar and forearm skin to 3% sodium lauryl sulfate in 9 healthy premenopausal women. TEWL, capacitance, pH, blood flow, and all parameters of color reflectance changed significantly in forearm irritant dermatitis. In vulvar irritant dermatitis, however, significant changes were observed (...) only for blood flow and the color reflectance parameters a* and b*. Using the combination of TEWL, capacitance and blood flow, forearm irritant dermatitis was detected with a sensitivity of 84% and a specificity of 100%. In this study, the best combination of parameters to detect vulvar irritant dermatitis was pH, blood flow, a* and b*, which had a sensitivity of 78% and a specificity of 75%. It is concluded that available bioengineering techniques are less suitable to quantify irritant dermatitis

1990 Contact dermatitis Controlled trial quality: uncertain

187. Sodium lauryl sulfate-induced irritant contact dermatitis in vulvar and forearm skin of premenopausal and postmenopausal women. (PubMed)

Sodium lauryl sulfate-induced irritant contact dermatitis in vulvar and forearm skin of premenopausal and postmenopausal women. Reactivity of the skin of the forearm and labia majora to three concentrations (2%, 3%, 5%) of sodium lauryl sulfate was studied in 20 healthy women, 10 premenopausal and 10 postmenopausal. Patches with the irritant were applied on day 0 for 24 hours. Skin changes were monitored by visual scoring and by the measurement of transepidermal water loss and capacitance (...) transepidermal water loss in monitoring vulvar irritant dermatitis. Age-related differences in irritant reaction are apparent in the forearm, but not the vulva.

1990 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>